← Leaderboards
Srinivas Ayyadevara
Univ Of Arkansas For Med Scis
$933,623
Attributed
$1,867,246
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $375K · FY2018–22$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,867,246 · 1
By mechanism
R01$1,867,246 · 1
Top collaborators
- Robert Joseph Shmookler-Reis5 shared
Most similar at Univ Of Arkansas For Med Scis
Same institution · by research overlap
- Steven W Barger$11,826,209
- Fusun Kilic$2,479,794
- Shengyu Mu$3,420,136
- Karen Hye-Cheon Kim Yeary$3,618,181
- Hari Eswaran$5,779,834
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAgedAge GroupAdultAge RelatedAgingAdhesion ProcessAmyloidAge-MonthsAmyloidosisAnalytical ToolAspirinBaseBrainCerebrumC57bl/6n MouseCachexiaCaenorhabditis ElegansCaloric RestrictionCandidate MarkerCardiovascular DiseasesCardiovascular Risk FactorCerebral AmyloidosisCharacteristics
Grant awards (5)
Inference of Common Pathways Underlying Neurodegeneration & Other Age-Progressive Diseases$374,971
R01 · FY2022 · AG
Inference of Common Pathways Underlying Neurodegeneration & Other Age-Progressive Diseases$374,971
R01 · FY2021 · AG
Inference of Common Pathways Underlying Neurodegeneration & Other Age-Progressive Diseases$374,771
R01 · FY2020 · AG
Inference of Common Pathways Underlying Neurodegeneration & Other Age-Progressive Diseases$372,368
R01 · FY2019 · AG
Inference of Common Pathways Underlying Neurodegeneration & Other Age-Progressive Diseases$370,165
R01 · FY2018 · AG